"A kinome-wide #CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer" Liu J [..] Liu X. Cell Rep Med 2023-04-18. https://t.co/Kjn6xcOa7X

🔬CRISPR-Cas9 screen reveals CK1α as a therapeutic target🎯 to overcome ENZA resistance of prostate cancer🦀. CK1α inhibition stabilizes ATM, restoring DSB signaling & ENZA-induced cell death💀. Intriguingly, FDA-approved CK1α inhibitor, BTX-A51, is in cli

A kinome-wide #CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of #prostatecancer #recentlypublished #happyeditor https://t.co/qjd4XGcTDB

RT @CellRepMed: Online now: A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer…

Online now: A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer https://t.co/BXmYNfMaAZ

💡 In this study led by Drs. Jinghui Liu and Xiaoqi Liu of @UKYMedicine, collaborators detail a therapeutic approach for enzalutamide-resistant #ProstateCancer, characterizing CK1α as a target to overcome this resistance. @CellRepMed | 🔓 https://t.co/IGOr3